Table 4.
Percent 1-year, 2-year, 5-year and 10-year net survival and 5|1-year and 5|2-year conditional net survival from total liver cancer, hepatocellular carcinoma, intrahepatic cholangiocarcinoma and ‘other liver cancer types’ by sex and period of diagnosis (Italy, 2003–2017).
| Type | Sex | Time since Diagnosis |
Net Survival, % (95% CI) | |||
|---|---|---|---|---|---|---|
| 2003–2007 | 2008–2012 | 2013–2017 | p-Value * | |||
| Total liver cancer | Men | 1 year | 50.1 (49.0; 51.3) | 54.1 (52.9; 55.2) | 55.7 (54.5; 56.9) | <0.001 |
| 2 years | 36.2 (35.1; 37.4) | 39.4 (38.2; 40.5) | 41.7 (40.5; 42.9) | <0.001 | ||
| 5 years | 18.1 (17.1; 19.1) | 20.5 (19.5; 21.6) | 22.7 (21.6; 23.9) | <0.001 | ||
| 10 years | 9.3 (8.5; 10.2) | 11.1 (10.2; 12.0) | 12.4 (11.4; 13.4) | <0.001 | ||
| 5|1 year | 35.3 (33.5; 37.0) | 37.3 (35.6; 39.1) | 39.8 (38.1; 41.5) | <0.001 | ||
| 5|2 years | 48.4 (46.1; 50.6) | 51.3 (49.2; 53.4) | 53.7 (51.4; 55.9) | <0.001 | ||
| Women | 1 year | 48.8 (46.6; 51.0) | 52.0 (49.9; 54.0) | 53.4 (51.3; 55.5) | 0.212 | |
| 2 years | 34.2 (32.0; 36.4) | 38.2 (36.1; 40.2) | 39.5 (37.3; 41.6) | 0.023 | ||
| 5 years | 18.2 (16.3; 20.2) | 21.4 (19.5; 23.3) | 21.9 (20.0; 23.8) | 0.007 | ||
| 10 years | 11.4 (9.7; 13.3) | 12.4 (10.8; 14.1) | 12.7 (11.1; 14.5) | 0.014 | ||
| 5|1 year | 35.9 (32.7; 39.0) | 39.4 (36.6; 42.3) | 39.4 (36.6; 42.3) | <0.001 | ||
| 5|2 years | 50.6 (46.7; 54.3) | 53.4 (50.1; 56.7) | 53.0 (49.2; 56.6) | 0.032 | ||
| Hepatocellular carcinoma | Men | 1 year | 61.2 (59.6; 62.8) | 63.0 (61.3; 64.5) | 65.2 (63.5; 66.7) | 0.001 |
| 2 years | 46.2 (44.5; 47.9) | 48.3 (46.6; 50.0) | 50.7 (49.0; 52.4) | <0.001 | ||
| 5 years | 24.5 (22.9; 26.0) | 26.8 (25.2; 28.4) | 28.9 (27.3; 30.6) | <0.001 | ||
| 10 years | 12.2 (11.0; 13.6) | 14.4 (13.0; 15.9) | 15.6 (14.1; 17.2) | <0.001 | ||
| 5|1 year | 39.3 (37.1; 41.6) | 42.3 (40.0; 44.5) | 43.9 (41.7; 46.1) | 0.002 | ||
| 5|2 years | 51.8 (49.0; 54.5) | 55.0 (52.4; 57.5) | 56.4 (53.5; 59.1) | 0.009 | ||
| Women | 1 year | 60.5 (56.9; 63.9) | 63.6 (60.5; 66.5) | 65.7 (62.4; 68.8) | 0.177 | |
| 2 years | 44.9 (41.2; 48.4) | 49.9 (46.6; 53.1) | 50.8 (47.3; 54.2) | 0.035 | ||
| 5 years | 24.9 (21.6; 28.4) | 29.6 (26.4; 32.8) | 30.1 (26.9; 33.5) | 0.007 | ||
| 10 years | 14.3 (11.3; 17.6) | 16.4 (13.5; 19.4) | 16.5 (13.7; 19.6) | 0.023 | ||
| 5|1 year | 41.0 (37.0; 44.9) | 44.5 (40.4; 48.5) | 44.9 (40.8; 48.9) | 0.011 | ||
| 5|2 years | 53.4 (48.6; 58.0) | 56.2 (51.6; 60.6) | 57.5 (52.5; 62.2) | 0.070 | ||
| Intrahepatic cholangiocarcinoma |
Men | 1 year | 36.3 (31.6; 40.9) | 44.4 (40.1; 48.6) | 44.8 (40.9; 48.6) | 0.090 |
| 2 years | 22.4 (18.2; 26.9) | 30.0 (25.9; 34.2) | 29.2 (25.6; 33.0) | 0.059 | ||
| 5 years | 9.7 (6.7; 13.3) | 12.3 (9.2; 15.8) | 13.9 (10.8; 17.3) | 0.057 | ||
| 10 years | 5.0 (2.9; 8.1) | 7.7 (5.1; 11.0) | 8.5 (5.6; 12.0) | 0.052 | ||
| 5|1 year | 27.3 (19.1; 36.2) | 27.1 (20.5; 34.2) | 30.7 (24.2; 37.5) | 0.367 | ||
| 5|2 years | 43.7 (31.2; 55.6) | 40.2 (30.8; 49.5) | 45.9 (34.8; 56.3) | 0.682 | ||
| Women | 1 year | 46.7 (41.0; 52.2) | 47.0 (42.2; 51.7) | 54.1 (49.5; 58.5) | 0.159 | |
| 2 years | 28.4 (23.1; 33.8) | 33.1 (28.5; 37.8) | 38.1 (33.5; 42.7) | 0.032 | ||
| 5 years | 12.8 (9.1; 17.2) | 14.2 (10.7; 18.1) | 17.4 (13.5; 21.7) | 0.037 | ||
| 10 years | 11.2 (6.8; 16.7) | 9.8 (6.5; 13.9) | 12.2 (8.3; 16.8) | 0.040 | ||
| 5|1 year | 28.5 (20.2; 37.3) | 30.3 (23.2; 37.8) | 32.3 (25.3; 39.4) | 0.116 | ||
| 5|2 years | 47.1 (34.1; 58.9) | 43.2 (33.5; 52.4) | 46.1 (35.9; 55.7) | 0.645 | ||
| Other liver cancer types | Men | 1 year | 38.5 (36.8; 40.2) | 45.7 (43.9; 47.4) | 46.6 (44.7; 48.4) | 0.001 |
| 2 years | 25.7 (24.1; 27.4) | 30.6 (28.9; 32.3) | 33.0 (31.1; 34.9) | <0.001 | ||
| 5 years | 11.2 (9.9; 12.6) | 14.4 (13.0; 15.8) | 16.6 (14.9; 18.4) | <0.001 | ||
| 10 years | 6.1 (5.0; 7.3) | 7.7 (6.5; 9.0) | 9.0 (7.6; 10.6) | <0.001 | ||
| 5|1 year | 28.2 (25.3; 31.2) | 30.7 (28.0; 33.5) | 34.2 (31.2; 37.1) | 0.002 | ||
| 5|2 years | 41.7 (37.7; 45.6) | 46.0 (42.3; 49.7) | 49.3 (45.3; 53.2) | 0.008 | ||
| Women | 1 year | 38.8 (35.6; 42.0) | 44.5 (41.2; 47.8) | 42.5 (39.1; 46.0) | 0.568 | |
| 2 years | 26.5 (23.3; 29.7) | 30.4 (27.3; 33.7) | 31.1 (27.8; 34.5) | 0.282 | ||
| 5 years | 14.3 (11.6; 17.3) | 18.1 (15.2; 21.1) | 17.5 (14.6; 20.5) | 0.253 | ||
| 10 years | 10.1 (7.5; 13.0) | 10.8 (8.3; 13.7) | 10.4 (8.0; 13.3) | 0.284 | ||
| 5|1 year | 34.3 (28.9; 39.7) | 39.0 (34.0; 43.9) | 39.2 (34.2; 44.2) | 0.160 | ||
| 5|2 years | 50.0 (43.3; 56.3) | 56.4 (50.6; 61.8) | 51.5 (44.7; 57.9) | 0.785 | ||
CI, confidence interval. * From the Wald test for trend in the exponential of the period of diagnosis coefficient. The period of diagnosis was entered as a continuous regressor in a Poisson regression model for net survival.